Chemical stability and cytotoxicity of human insulin loaded in cationic DPPC/CTA/DDAB liposomes

Journal of Biomedical Nanotechnology

Volumn 7, Issue 2, 2011, Pages 308-316

  Manosroi, Aranya ^a   Khositsuntiwong, Narinthorn ^a   Komno, Chonlada ^a   Manosroi, Worapaka ^c   Werner, Rolf G ^b   Manosoi, Jiradej ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Cationic liposomes; Chemical stability; CTA; Cytotoxicity; Human insulin

Indexed keywords

AMMONIUM BROMIDES; AVERAGE SIZE; CANCER CELL LINES; CATIONIC LIPIDS; CATIONIC LIPOSOMES; CTA; CYTOTOXIC EFFECTS; ENTRAPMENT EFFICIENCY; FILM METHOD; GEL FILTRATION; HUMAN SKIN FIBROBLAST; LIPOSOMAL FORMULATION; MOLAR RATIO; PHOSPHATIDYL CHOLINE; POTENTIAL APPLICATIONS; POTENTIAL VALUES; SPHERICAL SHAPE; THERAPEUTIC USE; UNILAMELLAR;

AMMONIUM COMPOUNDS; BROMINE COMPOUNDS; CELL CULTURE; CHEMICAL STABILITY; INSULIN; LIPOSOMES; PHOSPHOLIPIDS; ZETA POTENTIAL;

CYTOTOXICITY;

CATION; CHLOROFORM; CHOLEST 5 EN 3 OL (3 BETA)(TRIMETHYLAMMONIO)ACETATE; CHOLESTEROL DERIVATIVE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DIPALMITOYLPHOSPHATIDYLCHOLINE; HUMAN INSULIN; LIPID; LIPOSOME; UNCLASSIFIED DRUG; CHOLESTEROL; DIDODECYLDIMETHYLAMMONIUM; DRUG DERIVATIVE; INSULIN; NANOPARTICLE; QUATERNARY AMMONIUM DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; DRUG CYTOTOXICITY; DRUG STABILITY; ESTERIFICATION; GEL FILTRATION; HUMAN; HUMAN CELL; MOUTH CARCINOMA; PARTICLE SIZE; SEDIMENTATION; SKIN FIBROBLAST; TRANSMISSION ELECTRON MICROSCOPY; ULTRASOUND; ZETA POTENTIAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; METHODOLOGY;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; CELL LINE; CELL SURVIVAL; CHOLESTEROL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; INSULIN; LIPOSOMES; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; QUATERNARY AMMONIUM COMPOUNDS;

EID: 79960973034     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2011.1282     Document Type: Article

References (30)

1. P. D. Home, M. Massi-Benedetti, G. A. Shepherd, I. Hanning, K. G. M. M. Alberti, and D. R. Owens, A comparison of the activity and disposal of semi-synthetic human insulin and porcine insulin in normal man by the glucose clamp technique. Diabetologia 22, 41 (1982).
2. T. W. Van Haeften, Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care 12, 641 (1989).
3. J. Q. Oeswein and S. J. Shire, Peptide and protein drug delivery, edited by V. H. Lee, Marcel Dekker Inc, New York (1991), pp. 167-202.
4. A. B. Robinson and C. J. Rudd, Deamidation of glutaminyl and asparaginyl residues in peptides and proteins. Curr. Top. Cell. Regul. 8, 247 (1974).
5. T. Geiger and S. Clarke, Deamidation, isomerization, and racemization at asparginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J. Biol. Chem. 262, 785 (1987).
6. I. Morishita, K. Morishita, Y. Takayama, Y. Machida, and T. Nagai, Site-dependent effect of aprotinin, sodium caprate Na2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol. Pharm. Bull. 16, 68 (1993).
7. L. A. Bruce and P. Susanna, Metabolism of a neurotensin (8-13) analog by intestinal and nasal enzymes and approaches to stabilize this peptide at these absorption sites. Int. J. Pharm. 117, 95 (1993).
8. C. Michel, M. Aprehamian, L. Defontaine, P. Couvreur, and C. Damae, The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J. Pharm. Pharmacol. 43, 1 (1991).
9. P. G. Jemkin, K. A. Howard, N. W. Blackhall, N. W. Thomas, S. S. Davis, and D. T. O'Hagan, Microparticulate absorption from the rat intestine. J. Control. Release 29, 339 (1994).
10. C. Damage, D. Hillaire-Buys, R. Puech, A. Hoeltzel, C. Michel, and G. Ribes, Effects of orally administered insulin nanocapsuled in normal and diabetic dogs. Diabetes. Metab. 8, 3 (1995).
11. Y. Huang and C. Wang, Pulmonary delivery of insulin by liposomal carriers. J. Control. Release 113, 9 (2006).
12. A. Alaouie and S. Sofou, Liposomes with triggered content release for cancer therapy. J. Biomed. Nanotechnol. 4, 234 (2008).
13. M. Gaspar, U. Bakowsky, and C. Ehrhardt, Inhaled liposomescurrent strategies and future challenges. J. Biomed. Nanotechnol. 4, 245 (2008).
14. W. Zou, W. Sun, N. Zhang, and W. Xu, Enhanced oral bioavailability and absorption mechanism study of N3-O-toluyl-fluorouracil-loaded liposomes. J. Biomed. Nanotechnol. 4, 90 (2008).
15. Y. Hong and J. Kim, pH - And calcium ion-dependent release from egg phosphatidylcholine liposomes incorporating hydrophobically modified alginate. J. Nanosci. Nanotechnol. 10, 8380 (2010).
16. G. Zhai, J. Wu, B. Yu, C. Guo, X. Yang, and R. Lee, A transferring receptor-targeted liposomal formulation for docetaxel. J. Nanosci. Nanotechnol. 10, 5129 (2010).
17. G. Zhai, J. Wu, G. Xiang, W. Mao, B. Yu, H. Li, L. Piao, L. Lee, and R. Lee, Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. J. Nanosci. Nanotechnol. 9, 2155 (2009).
18. M. Gulati, M. Grover, S. Singh, and M. Singh, Lipophilic drug derivatives in liposomes. Int. J. Pharm. 165, 129 (1998).
19. L. Peltonen, P. Koistinen, M. Karjalainen, A. Hakkinen, and J. Hirvonen, The effect of cosolvents on the formulation of nanoparticles from low-molecular-weight Poly(l)lactide. Pharm. Sci. Tech. 3, 32 (2002).
20. E. Mourelatou, E. Spyratou, A. Georgopoulos, M. Makropoulou, E. Liandris, M. Gazouli, J. Ikonomopoulos, and C. Demetzos, Development and characterization of oligonucleotide-tagged dye-encapsulating EPC/DPPG Liposomes. J. Nanosci. Nanotechnol. 10, 5548 (2010).
21. R. Bajoria, S. R. Sooranna, and S. F. Contractor, Endocytotic uptake of small unilamella liposomes by human trophoblast cells in culture. Hum. Reprod. 12, 1343 (1997).
22. P. Barbugli, M. Siqueira-Moura, E. Espreafico, and A. Tedesco, In vitro phototoxicity of liposomes and nanocapsules containing chloroaluminum pthalocyanine on human melanoma cell line. J. Nanosci. Nanotechnol. 10, 569 (2010).
23. S. Mourtas, G. Michanetzis, Y. Missirlis, and S. Antimisiaris, Haemolytic activity of liposomes: Effect of vesicle size, lipid concentration and polyethylene glycol-lipid or arsonolipid incorporation. J. Biomed. Nanotechnol. 5, 409 (2009).
24. A. Miguel, R. B. Castanho, C. Nuno, S. Santos, and M. S. Luís, Separating the turbidity spectra of vesicles from the absorption spectra of membrane probes and other chromophores. Eur. Biophys. J. 26, 253 (1997).
25. K. Iwanaga, S. Ono, K. Narioka, K. Morimoto, M. Kakemi, S. Yamashita, M. Nango, and N. Oku, Oral delivery of insulin by using surface coating liposomes: Improvement of stability of insulin in GI tract. Int. J. Pharm. 157, 73 (1997).
26. Y. K. Ghosh, S. S. Visweswariah, and S. Bhattacharya, Nature of linkage between the cationic headgroup and cholesteryl skeleton controls gene transfection efficiency. FEBS Lett. 473, 341 (2000).
27. A. Manosroi, L. Kongkaneramit, and J. Manosroi, Stability and transdermal absorption of topical amphotericin B liposome formulations. Int. J. Pharm. 270, 279 (2004).
28. C. Sentein, B. Guizard, S. Giraud, C. Ye, and F. Ténégal, Dispersion and stability of TiO2 nanoparticles synthesized by laser pyrolysis in aqueous suspensions. J. Phys. Conf. 170, 12 (2009).
29. G. N. Shriniwas and K. G. Kanwal, Insulin degradation by human erytracyle lysates. CLIN. Chem. 27, 607 (1981).
30. A. Manosroi, K. Thathang, R. G. Werner, R. Schubert, and J. Manosroi, Stablilty of luciferase plasmid entrapped in cationic bilayer vesicles. Int. J. Pharm. 356, 291 (2008).